Search
wechseln zu deutsch deutsch english
Home General For Authors Subscription Full Text Articles

 

Sci. Pharm. 2009; 77: 651–667

Design and Development of a Self Correcting Monolithic Gastroretentive Tablet of Baclofen

Rishad R. JIVANI * 1, Chhagan N. PATEL 2, Nuruddin P. JIVANI 1

1 Smt. R.B.Patel Mahila Pharmacy College, Kailash nagar, Dist: Rajkot, Atkot-360040, Gujarat, India.
2 Shari Sarvajanik Pharmacy College, Mehsana-384001, Gujarat, India.

* Corresponding author. E-mail: hellorishad@yahoo.com (R. R. Jivani).

Abstract

The present investigation describes the design and development of self-correcting monolithic Gastroretentive system of baclofen. Tablets were prepared by direct compression method. Optimization was carried out using simplex lattice design. Drug released at 2h, 4h, 8h, and floating lag time were considered as response variables related to percentages of diluent (MCC), Polyethylene oxide (PEO) and sodium bicarbonate. Tablets were evaluated for in-vitro buoyancy, in-vitro drug release, swelling index and ex-vivo bioadhesion studies. The similarity factor (f2) was used as a base to compare dissolution profiles. Drug release data was fitted into different kinetic models. The floating lag time and floating time were found to be 2min and 12h respectively. Increasing trend in bioadhesive strength was observed with an increase in the amount of PEO. The experimental values of Q2, Q4 and Q8 for check point batch were found to be 30.8%, 44.1% and 69.9% respectively. Similarity factor (f2) for check point batch was 78.08. Kinetics of drug release from tablet followed Korsmeyer–Peppas model by anamolous non-fickian diffusion. It was concluded that gastroretentive tablet of baclofen can be prepared via floating and bioadhesion mechanism to increase residence time of drug in stomach and there by increases absorption.

Keywords

Baclofen • Gastro retentive drug delivery system • Simplex lattice design • Polyethylene oxide (PEO)

Received May 17th, 2009 | Accepted July 21st, 2009 | Published Online July 24th, 2009

doi:10.3797/scipharm.0905-11